PressJune 26, 2024 atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
PressJune 25, 2024 Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
PressJune 25, 2024 Health Canada Issues Three Export Permits to Optimi to Supply Patients Under Australia’s Authorised Prescriber Scheme
PressJune 24, 2024 Hypha Labs, Inc. Reveals New Patent Applications for Novel Artificial Intelligence (A.I.) Driven In-Home Mycelium Production
PressJune 20, 2024 MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
PressJune 20, 2024 Atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
PressJune 20, 2024 Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
PressJune 19, 2024 Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
PressJune 19, 2024 Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
PressJune 14, 2024 Largest Study of Psychedelic Medicine, with 11,441 Mindbloom Clients, Demonstrates Effectiveness and Safety of Guided At-Home Ketamine Therapy
PressJune 13, 2024 Filament Health Announces Closing of Warrant Exercise, Note Conversion and Concurrent Private Placement of Common Shares
PressJune 12, 2024 Mindbio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
PressJune 12, 2024 Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
PressJune 11, 2024 Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
PressJune 11, 2024 Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
PressJune 11, 2024 Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
PressJune 11, 2024 Optimi Health Completes First International Shipment of MDMA to Israel and Secures CBSA Exporters Authorization ID
PressJune 7, 2024 Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD
PressJune 7, 2024 Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
